All In Biotech

NDA 201277 · Bayer Hlthcare

Gadavist

Gadobutrol · Intravenous · Gadolinium-based Contrast Agent

Novel

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Mar 14, 2011

Approved uses

5

Original approval plus efficacy supplements

Registered trials

63

22 Phase 3, 10 recruiting

FAERS reports

4,907

2,187 serious, 189 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. GADAVIST is not approved for intrathecal use [see Warnings and Precautions (5.1) ]. Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of GADAVIST in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: Chronic, severe kidney disease (GFR < 30 mL/min/1.73m 2 ), or Acute kidney injury....

What it is approved for

From the label in effect Sep 11, 2026.

GADAVIST is indicated for: Magnetic resonance imaging (MRI) of the central nervous system (CNS) to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity in adult and pediatric patients including term neonates MRI of the breast to assess the presence and extent of malignant breast disease in adult patients Magnetic resonance angiography (MRA) to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients including term neonates Cardiac MRI (CMRI) to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD) GADAVIST is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI): To detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients including term neonates To assess the presence and extent of malignant breast disease in adult patients To evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients including term neonates To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD) ( 1 )

Mechanism: Gadobutrol is a paramagnetic molecule (macrocyclic non-ionic complex of gadolinium) that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • GADAVIST · GADOBUTROL 18.1416GM/30ML (604.72MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • GADAVIST · GADOBUTROL 6.0472GM/10ML (604.72MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • GADAVIST · GADOBUTROL 39.3068GM/65ML (604.72MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • GADAVIST · GADOBUTROL 9.0708GM/15ML (604.72MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • GADAVIST · GADOBUTROL 4.5354GM/7.5ML (604.72MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • GADAVIST · GADOBUTROL 1.20944GM/2ML (604.72MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Gadobutrol" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • urticaria1,188
  • nausea890
  • vomiting742
  • pruritus730
  • dyspnoea455
  • erythema375
  • dizziness244
  • rash244
  • cough231
  • headache222
  • throat irritation184
  • contrast media reaction168

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
2011103
2012442
2013327
2014364
2015317
2016373
2017414
2018310
2019266
2020177
2021325
2022307
2023330
2024353
2025301
2026197

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Gadavist* (Gadobutrol*) · HCPCS A9585

2024 spending

$6.7M

Beneficiaries

224,477

263,032 claims

Per beneficiary

$30

2024 ASP limit $0.32 per unit

View as table
YearSpending
2020$6,005,367
2021$6,792,125
2022$6,535,733
2023$6,720,565
2024$6,698,098

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 94 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.